Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis

Journal of Infectious Diseases

Volumn 187, Issue 1, 2003, Pages 70-76

  Opal, Steven M ^a,c   Keith Jr , James C ^b   Jhung, Jhung ^a   Palardy, John E ^a   Parejo, Nicolas ^a   Marchese, Erik ^b   Maganti, Vasu ^b  

^a BROWN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAMANDOLE; CYCLOPHOSPHAMIDE; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 11 RECEPTOR; RECOMBINANT INTERLEUKIN 11; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENTERIC COATED TABLET; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GRAM NEGATIVE SEPSIS; INFECTION PREVENTION; INTESTINE CELL; INTESTINE EPITHELIUM CELL; KAPLAN MEIER METHOD; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RAT; SEPSIS; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANIMALS; BACTEREMIA; FEMALE; INTERFERON TYPE II; INTERLEUKIN-11; NEUTROPENIA; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037217772     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345864     Document Type: Article

References (26)

1. Du XX, Williams DA. Interleukin-11: A multifunctional growth factor derived from the hematopoietic micro-environment. Blood 1994; 83:2023-30.
2. Neddermann P, Graziani R, Caliberto G, Paonessa G. Functional expression of soluble interleukin- 11 (IL- 11) receptor alpha and stoichiometry of in vitro IL-11 receptor complexes with GP130. J Biol Chem 1996; 271:30986-91.
3. Dorner AJ, Goldman SJ, Keith JC Jr. Interleukin-11: Biological activity and clinical studies. Biodrugs 1997; 8:418-29.
4. Grosfeld JL, Du X, Williams DA. Interleukin-11: Its biology and prospects for clinical use. JPEN J Parenter Enteral Nutr 1999; 23(Suppl 5): S67-9.
5. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of human recombinant interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87:3607-14.
6. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J Immunol 1997; 159:5661-9.
7. Trepicchio WL, Bozza M, Pednuit G, Dorner AJ. Recombinant human interleukin-11 attenuates the inflammatory response through down-regulation of pro-inflammatory cytokine release and nitric oxide production. J Immunol 1996; 157:3627-34.
8. Trepicchio WL, Ozawa M, Waiters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104:1527-37.
9. Fiore NF, Lediczky G, Liu Q, et al. Comparison of interleukin-11 and epidermal growth factor on residual small bowel intestine after massive small bowel resection. J Pediatr Surg 1998; 33:24-9.
10. Du XX, Liu Q, Yang Z. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol 1997; 272:G545-52.
11. Orazi A, Du XX, Yang Z, Kashai M, Williams DA. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 1996; 75:33-40.
12. Potten CS. Interleukin-11 protects the clonogenic stem cells in murine small intestinal mucosa from impairment of their reproductive capacity by radiation. Int J Cancer 1995; 62:356-61.
13. Hill GR, Cooke KR, Teshima T. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102:115-23.
14. Peterson RL, Bozza MM, Dorner AJ. Interleukin-11 induces intestinal epithelial growth arrest through effects on retinoblastoma protein phosphorylation. Am J Pathol 1996; 149:895-902.
15. Tseng Leo C-M, Albert L, Peterson RL. In vivo absorption properties of orally administered recombinant human interleukin-11. Pharm Res 2000; 17:482-5.
16. Opal SM, Jhung JW, Keith JC Jr, et al. Human recombinant interleukin-11 in the treatment of immunocompromised animals with experimental Pseudomonas aeruginosa sepsis. J Infect Dis 1998; 178:1205-8.
17. Keith JC Jr, Albert A, Sonis ST, Pfeiffer CJ, Schaub RG. Interleukin-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994; 12(Suppl):79-90.
18. Opal SM, Jhung JW, Keith JC Jr, et al. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood 1999; 93:3467-72.
19. Peterson RL, Wang L, Keith JC Jr, Dorner AJ. Molecular effects of recombinant human interleukin-11 in the HLA B27 rat model of inflammatory bowel disease. Lab Invest 1998; 78:1503-12.
20. Kruse N, Pette M, Tokya K, Rieckman P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods 1997; 210:195-203.
21. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6:986-94.
22. Van Leuven F, Stas I, Killiker C, et al. Molecular cloning and characterization of the human interleukin-11 receptor α chain gene, IL-11RA, located on chromosome 9p13. Genomics 1996; 31:65-9.
23. Nandurkar HH, Robb L, Tarlinton D, et al. Adult mice with targeted mutation of the interleukin-11 receptor (IL 11Ra) display normal hematopoiesis. Blood 1997; 90:2148-59.
24. Opal SM, Keith JC Jr. The activity of interleukin-11 in the gastrointestinal tract. Curr Opin Crit Care 2000; 6:148-52.
25. Greenwood-Van Meerveld B, Tyler K, Keith JC Jr. Recombinant human interleukin-11 modulates mucosal ion transport in the small intestine and colon of normal and HLA-B27 rats in vitro. Lab Invest 2000; 80:1269-80.
26. Sands BE, Bank S, Srinsky CA, et al. Preliminary evaluation of recombinant human interleukin-11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64.